HALO Halozyme Therapeutics Inc

Price (delayed)

$42.79

Market cap

$6.09B

P/E Ratio

35.66

Dividend/share

N/A

EPS

$1.2

Enterprise value

$6.47B

Highlights
HALO's gross profit has soared by 134% YoY and by 23% QoQ
The company's revenue has surged by 102% YoY and by 24% QoQ
The company's equity has shrunk by 55% QoQ but it rose by 16% YoY
The debt has soared by 124% YoY and by 120% from the previous quarter
Halozyme Therapeutics's quick ratio has decreased by 16% YoY

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
142.39M
Market cap
$6.09B
Enterprise value
$6.47B
Valuations
Price to earnings (P/E)
35.66
Price to book (P/B)
85.63
Price to sales (P/S)
17.82
EV/EBIT
35.83
EV/EBITDA
35.21
EV/Sales
19.52
Earnings
Revenue
$331.26M
EBIT
$180.48M
EBITDA
$183.64M
Free cash flow
$116.27M
Per share
EPS
$1.2
Free cash flow per share
$0.84
Book value per share
$0.5
Revenue per share
$2.4
TBVPS
$7.01
Balance sheet
Total assets
$966.58M
Total liabilities
$898.99M
Debt
$873.77M
Equity
$67.6M
Working capital
$834.3M
Liquidity
Debt to equity
12.93
Current ratio
8.77
Quick ratio
7.94
Net debt/EBITDA
2.04
Margins
EBITDA margin
55.4%
Gross margin
83.2%
Net margin
49.2%
Operating margin
59.8%
Efficiency
Return on assets
25.1%
Return on equity
154.1%
Return on invested capital
22.4%
Return on capital employed
21%
Return on sales
54.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
2.56%
1 week
8.41%
1 month
0.26%
1 year
85.88%
YTD
0.19%
QTD
2.64%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$331.26M
Gross profit
$275.46M
Operating income
$198.21M
Net income
$163.08M
Gross margin
83.2%
Net margin
49.2%
HALO's gross profit has soared by 134% YoY and by 23% QoQ
The company's revenue has surged by 102% YoY and by 24% QoQ
The company's operating income rose by 37% QoQ
HALO's net income is up by 26% since the previous quarter

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
P/E
35.66
P/B
85.63
P/S
17.82
EV/EBIT
35.83
EV/EBITDA
35.21
EV/Sales
19.52
HALO's EPS is up by 26% since the previous quarter
HALO's price to book (P/B) is 180% higher than its 5-year quarterly average of 30.6 and 78% higher than its last 4 quarters average of 48.1
The company's equity has shrunk by 55% QoQ but it rose by 16% YoY
The company's revenue has surged by 102% YoY and by 24% QoQ
The price to sales (P/S) is 38% higher than the 5-year quarterly average of 12.9 but 8% lower than the last 4 quarters average of 19.3

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has grown by 23% from the previous quarter
HALO's return on sales is down by 2.5% since the previous quarter
Halozyme Therapeutics's return on assets has increased by 3.3% QoQ

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 8% higher than its total liabilities
The total liabilities has surged by 110% since the previous quarter and by 107% year-on-year
The company's total assets has surged by 96% YoY and by 67% QoQ
The debt has soared by 124% YoY and by 120% from the previous quarter
Halozyme Therapeutics's debt to equity has soared by 93% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.